[go: up one dir, main page]

LT3288940T - Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių - Google Patents

Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių

Info

Publication number
LT3288940T
LT3288940T LTEP16723204.0T LT16723204T LT3288940T LT 3288940 T LT3288940 T LT 3288940T LT 16723204 T LT16723204 T LT 16723204T LT 3288940 T LT3288940 T LT 3288940T
Authority
LT
Lithuania
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
ampa
modulators
Prior art date
Application number
LTEP16723204.0T
Other languages
English (en)
Inventor
Cynthia G.B. BERRY
Gang Chen
Fabrice Loic JOURDAN
Terry Patrick LEBOLD
David Wei LIN
Miguel Angel PENA PIÑ N
Suchitra Ravula
Bradley M. SAVALL
Devin M. Swanson
Dongpei Wu
Wei Zhang
Michael K. Ameriks
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LT3288940T publication Critical patent/LT3288940T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP16723204.0T 2015-04-29 2016-04-28 Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių LT3288940T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
LT3288940T true LT3288940T (lt) 2021-05-10

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16723204.0T LT3288940T (lt) 2015-04-29 2016-04-28 Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių

Country Status (39)

Country Link
US (5) US11312712B2 (lt)
EP (3) EP3288940B9 (lt)
JP (2) JP6800886B2 (lt)
KR (2) KR102782808B1 (lt)
CN (1) CN107835814B (lt)
AR (1) AR104447A1 (lt)
AU (2) AU2016255434C1 (lt)
BR (2) BR122023023802A2 (lt)
CA (1) CA2983826A1 (lt)
CO (1) CO2017011017A2 (lt)
CR (1) CR20170484A (lt)
CY (1) CY1124059T1 (lt)
DK (1) DK3288940T5 (lt)
EA (1) EA033281B1 (lt)
EC (1) ECSP17074645A (lt)
ES (1) ES2865330T3 (lt)
GT (1) GT201700231A (lt)
HR (1) HRP20210403T1 (lt)
HU (1) HUE053943T2 (lt)
IL (1) IL254848B (lt)
JO (1) JO3654B1 (lt)
LT (1) LT3288940T (lt)
MA (1) MA41988B1 (lt)
MD (1) MD3288940T2 (lt)
MX (1) MX376113B (lt)
MY (1) MY194104A (lt)
NI (1) NI201700129A (lt)
PH (1) PH12017501816B1 (lt)
PL (1) PL3288940T3 (lt)
PT (1) PT3288940T (lt)
RS (1) RS61688B1 (lt)
SG (1) SG11201708190UA (lt)
SI (1) SI3288940T1 (lt)
SM (1) SMT202100222T1 (lt)
TW (1) TWI706952B (lt)
UA (1) UA120304C2 (lt)
UY (1) UY36654A (lt)
WO (1) WO2016176460A1 (lt)
ZA (1) ZA201708065B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3288940T5 (da) 2015-04-29 2021-09-20 Janssen Pharmaceutica Nv Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
WO2016176457A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
ES2971497T3 (es) 2017-10-06 2024-06-05 Takeda Pharmaceuticals Co Compuestos heterocíclicos
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
MX2021005012A (es) * 2018-10-30 2021-07-21 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
PE20220139A1 (es) 2019-02-13 2022-01-27 Ptc Therapeutics Inc Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar
JP7617076B2 (ja) * 2019-07-22 2025-01-17 リペア セラピューティクス インコーポレイテッド Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法
CN117402148A (zh) * 2023-07-26 2024-01-16 青岛大学 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用
WO2025155830A1 (en) 2024-01-17 2025-07-24 Rapport Therapeutics, Inc. Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy
KR20250113344A (ko) * 2024-01-17 2025-07-25 주식회사 엘지화학 CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (lt) 1992-11-02 1995-07-11 Pfizer
WO1995021836A1 (en) 1994-02-10 1995-08-17 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
WO1999045007A1 (en) 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo[4,3-b]pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (en) * 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
MXPA01006742A (es) 1998-12-31 2004-04-21 Sugen Inc Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MX2007002604A (es) * 2004-09-03 2007-04-25 Applied Research Systems Azolidinonas de piridina metileno y uso de las mismas.
DE602006019119D1 (de) 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US20110312938A1 (en) * 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
PH12012501621A1 (en) 2010-02-11 2012-10-22 Univ Vanderbilt Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2011156245A2 (en) * 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
AR081976A1 (es) 2010-06-24 2012-10-31 Takeda Pharmaceutical Compuestos heterociclicos fusionados y sus usos como inhibidor de la fosfodiesterasa
LT2603513T (lt) 2010-08-10 2020-05-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus
US8993779B2 (en) 2010-08-12 2015-03-31 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
DK3288940T5 (da) 2015-04-29 2021-09-20 Janssen Pharmaceutica Nv Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
KR102417483B1 (ko) 2016-10-26 2022-07-05 얀센 파마슈티카 엔.브이. 융합된 아자헤테로사이클릭 화합물 및 ampa 수용체 조절제로서의 이들의 용도
JP6953527B2 (ja) 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
EP3774739B1 (en) 2018-04-09 2022-05-11 RaQualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途

Also Published As

Publication number Publication date
US12304908B2 (en) 2025-05-20
CY1124059T1 (el) 2022-05-27
PH12017501816A1 (en) 2018-04-23
UA120304C2 (uk) 2019-11-11
NZ774642A (en) 2024-09-27
EP3901153A1 (en) 2021-10-27
US20210284641A1 (en) 2021-09-16
KR20240017991A (ko) 2024-02-08
MY194104A (en) 2022-11-11
NI201700129A (es) 2019-05-10
JO3654B1 (ar) 2020-08-27
WO2016176460A1 (en) 2016-11-03
MA41988A (fr) 2018-07-03
SG11201708190UA (en) 2017-11-29
AU2016255434B2 (en) 2020-05-14
ES2865330T3 (es) 2021-10-15
ZA201708065B (en) 2019-09-25
NZ736057A (en) 2023-08-25
EP3288940B9 (en) 2021-07-21
TWI706952B (zh) 2020-10-11
AR104447A1 (es) 2017-07-19
DK3288940T3 (da) 2021-05-25
SMT202100222T1 (it) 2021-05-07
US12145934B2 (en) 2024-11-19
BR112017023147A2 (pt) 2018-07-10
EP3288940A1 (en) 2018-03-07
PT3288940T (pt) 2021-04-30
MX2017013886A (es) 2018-03-12
IL254848A0 (en) 2017-12-31
AU2016255434A1 (en) 2017-10-26
EA033281B1 (ru) 2019-09-30
CA2983826A1 (en) 2016-11-03
RS61688B1 (sr) 2021-05-31
US20230114165A1 (en) 2023-04-13
BR112017023147B1 (pt) 2024-04-30
HRP20210403T1 (hr) 2021-10-29
UY36654A (es) 2016-10-31
IL254848B (en) 2021-01-31
HK1252249A1 (en) 2019-05-24
TW201708217A (zh) 2017-03-01
HUE053943T2 (hu) 2021-08-30
JP6800886B2 (ja) 2020-12-16
AU2016255434C1 (en) 2021-09-23
US20250230157A1 (en) 2025-07-17
JP2018518462A (ja) 2018-07-12
PL3288940T3 (pl) 2021-07-12
MD3288940T2 (ro) 2021-08-31
DK3288940T5 (da) 2021-09-20
US11312712B2 (en) 2022-04-26
US12139485B2 (en) 2024-11-12
MA41988B1 (fr) 2021-03-31
CN107835814A (zh) 2018-03-23
MX376113B (es) 2025-03-07
CR20170484A (es) 2018-02-26
EP4144736A1 (en) 2023-03-08
CN107835814B (zh) 2021-07-23
US20230110576A1 (en) 2023-04-13
ECSP17074645A (es) 2018-02-28
PH12017501816B1 (en) 2023-07-19
AU2020210231B2 (en) 2021-07-22
KR102782808B1 (ko) 2025-03-14
CO2017011017A2 (es) 2018-03-20
JP7026194B2 (ja) 2022-02-25
SI3288940T1 (sl) 2021-07-30
EA201792374A1 (ru) 2018-05-31
JP2021042230A (ja) 2021-03-18
KR20170140382A (ko) 2017-12-20
GT201700231A (es) 2018-12-20
EP3288940B1 (en) 2021-02-24
US20180118740A1 (en) 2018-05-03
AU2020210231A1 (en) 2020-08-20
BR122023023802A2 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
LT3288940T (lt) Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3331877T (lt) Pirazolpirimidino dariniai ir jų panaudojimas
LT3363438T (lt) Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3148579T (lt) Anti-gitr antikūnai ir jų panaudojimo būdai
LT3484865T (lt) Somatostatino moduliatoriai ir jų panaudojimas
LT3319963T (lt) Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
DK3189056T3 (da) Cytotoksiske benzodiazepinderivater
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
HUE054245T2 (hu) Immunszupresszáns formuláció
LT3337506T (lt) Deriniai ir jų panaudojimas
EP3374386C0 (en) PROTEASE-ACTIVATED RECEPTOR TYPE 2 MODULATORS
IL246599A0 (en) Selective nr2b antagonists
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
EP3632505C0 (en) NON-INVASIVE NEUROMODULATION
BR112016027580A2 (pt) Formulação de ceritinib
DK3193856T3 (da) Formulering
CL2016001839A1 (es) Formulación de suministro tópico
TH1501006596A (th) สารประกอบไบเฮทเทอโรแอริล และการใช้งานของพวกมัน
ITRM20140170U1 (it) Dispositivo anti-tromboembolico
FI10914U1 (fi) Käsituki
UA30137S (uk) Підлокітник
PL2896314T3 (pl) Szminka do ust